Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
Accession Number
DB10076
Description

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type b. H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis. The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid 1. The toxoid antigen is purified and toxin-inactivated.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated / Toxoid / Conjugate
Synonyms
  • Haemophilus influenzae type B strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ActHIBKit10 ug/0.5mLIntramuscularSanofi Pasteur Inc.1993-03-30Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Act-hibHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg)Kit; Powder, for solutionIntramuscularSanofi Pasteur Limited1992-12-31Not applicableCanada flag
MenhibrixHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)KitIntramuscularGlaxoSmithKline Biologicals SA2013-09-032017-09-17US flag
MenhibrixHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)Injection, powder, lyophilized, for solutionIntramuscularGlaxoSmithKline Biologicals SA2013-09-032013-11-27US flag
PentacelHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL)IntramuscularSanofi Pasteur Inc.2008-06-20Not applicableUS flag
PentacelHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL)IntramuscularSanofi Pasteur Inc.2008-06-20Not applicableUS flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
FLV5I5W26R
CAS number
Not Available

References

General References
  1. Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen [Link]
PubChem Substance
347910467
RxNav
1300464

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedTreatmentPain1
3Active Not RecruitingPreventionInfections, Pneumococcal1
3Active Not RecruitingPreventionInfections, Pneumococcal / Vaccines, Pneumococcal1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionBacterial Infections / Virus Diseases2
3CompletedPreventionDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus2
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Tetanus1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Whooping Cough1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Kit; powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular10 µg/0.5mL
KitIntramuscular10 ug/0.5mL
Injection, powder, lyophilized, for solutionIntramuscular
KitIntramuscular
Injection, powder, for suspensionIntramuscular30 IU/0.5ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on November 30, 2015 14:23 / Updated on June 12, 2020 10:52

Logo pink
Combine AI with DrugBank’s data
to build predictive models.
Our clients have developed successful models for drug targets, side effects, toxicity, and drug-drug interactions. Learn More.